{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T07:09:26Z","timestamp":1648624166148},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,4,19]],"date-time":"2015-04-19T00:00:00Z","timestamp":1429401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00108-014-3628-1","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T06:05:20Z","timestamp":1429509920000},"page":"493-502","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medikament\u00f6se und Insulintherapie bei Diabetes mellitus Typ\u00a02"],"prefix":"10.1007","volume":"56","author":[{"given":"E.","family":"Siegel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,19]]},"reference":[{"key":"3628_CR1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1507\/endocrj.EJ11-0113","volume":"J","author":"Imamura","year":"2011","unstructured":"Imamura M, Maeda S (2011) Genetics of type\u00a02 diabetes: the GWAS era and future perspectives. Endocr\u00a0J 58:723\u2013739","journal-title":"Endocr"},{"key":"3628_CR2","doi-asserted-by":"crossref","unstructured":"Schipf S, Ittermann T, Tamayo T et\u00a0al (2014) Regional differences in the incidence of self-reported type\u00a02 diabetes in Germany: results from five population-based studies in Germany (DIAB-CORE Consortium). J\u00a0Epidemiol Community Health 68:1088\u20131095","DOI":"10.1136\/jech-2014-203998"},{"key":"3628_CR3","unstructured":"Stellungnahme der AG Epidemiologie der Deutschen Diabetes-Gesellschaft zum IDF Diabetes Atlas: Wie h\u00e4ufig ist Typ\u00a02-Diabetes in Deutschland? Vom 17.\u00a0August 2011. http:\/\/www.deutsche-diabetes-gesellschaft.de\/fileadmin\/Redakteur\/Stellungnahmen\/Stellungnahme_AG_EPI_310511.pdf"},{"key":"3628_CR4","doi-asserted-by":"crossref","unstructured":"Seshasai SR, Kaptoge S, Thompson A et\u00a0al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N\u00a0Engl J Med 364:829\u2013841","DOI":"10.1056\/NEJMoa1008862"},{"key":"3628_CR5","doi-asserted-by":"crossref","first-page":"f4533","DOI":"10.1136\/bmj.f4533","volume":"347","author":"Goto","year":"2013","unstructured":"Goto A, Arah Odio A et\u00a0al (2013) Severe hypoglycaemia and cardiovascular disease: systematic review and meta analysis with bias analysis. BMJ 347:f4533","journal-title":"BMJ"},{"key":"3628_CR6","doi-asserted-by":"crossref","unstructured":"Zoungas S, Patel A, Chalmers J et\u00a0al (2010) Severe hypoglycaemia and risks of vascular events and death. N\u00a0Engl J Med 363:1410\u20131418","DOI":"10.1056\/NEJMoa1003795"},{"key":"3628_CR7","unstructured":"Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes. http:\/\/www.leitlinien.de\/nvl\/diabetes\/therapie"},{"key":"3628_CR8","first-page":"S534","volume":"56","author":"Paul","year":"2013","unstructured":"Paul S, Thorsted BL, Wolden M et\u00a0al (2013) Delay in treatment intensification increases the risk of cardiovascular events in patients with type\u00a02 diabetes. Diabetologia 56(Suppl\u00a01):S534\u2013S535","journal-title":"Diabetologia"},{"key":"3628_CR9","first-page":"466","volume":"109","author":"Breuer","year":"2012","unstructured":"Breuer TG, Meier JJ (2012) Inpatient treatment of type\u00a02 diabetes. Dtsch Arztebl Int 109:466\u2013474","journal-title":"Dtsch Arztebl Int"},{"key":"3628_CR10","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"o","year":"1998","unstructured":"o\u00a0A (1998) Effect of intensive blood \u2013 glucose control with metformin on complications in overweight patients with type\u00a02 diabetes (UKPDS\u00a034). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854\u2013865","journal-title":"Lancet"},{"key":"3628_CR11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2337\/dc10-1287","volume":"34","author":"Monami","year":"2011","unstructured":"Monami M, Colombi C, Balzi D et\u00a0al (2011) Metformin and cancer occurrence in insulin-treated type\u00a02 diabetic patients. Diabetes Care 34:129\u2013131","journal-title":"Diabetes Care"},{"key":"3628_CR12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2407-11-20","volume":"11","author":"Lee","year":"2011","unstructured":"Lee MS, Hsu CC, Wahlqvist ML et\u00a0al (2011) Type\u00a02 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000\u00a0individuals. BMC Cancer 11:20","journal-title":"BMC Cancer"},{"key":"3628_CR13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-154-10-201105170-00007","volume":"154","author":"Gross","year":"2011","unstructured":"Gross JL, Kramer CK, Leitao CB et\u00a0al (2011) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type\u00a02 diabetes: a network meta-analysis. Ann Intern Med 154:672\u2013679","journal-title":"Ann Intern Med"},{"key":"3628_CR14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00132-009-1452-4","volume":"38","author":"Zander","year":"2009","unstructured":"Zander JF, Risse A (2009) Perioperative Behandlung und Einstellung des Diabetes mellitus. Orthopade 38:818\u2013827","journal-title":"Orthopade"},{"key":"3628_CR15","unstructured":"Rote Liste Service GmbH: Fachinformationsverzeichnis Deutschland. http:\/\/www.fachinfo.de. Zugegriffen: 6.\u00a0Januar 2014"},{"key":"3628_CR16","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2013) Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes \u2013 Langfassung, 1.\u00a0Aufl. Version\u00a01. http:\/\/www.versorgungsleitlinien.de\/themen\/diabetes2\/dm2_Therapie. Zugegriffen: 6.\u00a0Januar 2014"},{"key":"3628_CR17","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","volume":"28","author":"Eurich","year":"2005","unstructured":"Eurich DT, Majumdar SR, McAlister FA et\u00a0al (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345\u20132351","journal-title":"Diabetes Care"},{"key":"3628_CR18","unstructured":"Montamat SC, Cuack BJ, Vestal RE (1989) Management of drug therapy in the elderly. N\u00a0Engl J Med 308:303\u2013309"},{"key":"3628_CR19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1503\/cmaj.051237","volume":"174","author":"Bell","year":"2006","unstructured":"Bell DS (2006) Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 174:185\u2013186","journal-title":"CMAJ"},{"key":"3628_CR20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/heart.90.1.9","volume":"90","author":"Meier","year":"2004","unstructured":"Meier JJ, Gallwitz B, Schmidt WE et\u00a0al (2004) Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 90:9\u201312","journal-title":"Heart"},{"key":"3628_CR21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00125-014-3372-z","volume":"58","author":"Mogensen","year":"2015","unstructured":"Mogensen UM, Andersson C, Fosbol EL et\u00a0al (2015) Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study. Diabetologia 58:50\u201358","journal-title":"Diabetologia"},{"key":"3628_CR22","doi-asserted-by":"crossref","unstructured":"White WB, Cannon CP, Heller SR et\u00a0al (2013) Alogliptin after acute coronary syndrome in patients with type\u00a02 diabetes. N\u00a0Engl J Med 369:1327\u20131335","DOI":"10.1056\/NEJMoa1305889"},{"key":"3628_CR23","doi-asserted-by":"crossref","unstructured":"Scirica BM, Bhatt DL, Braunwald E et\u00a0al (2013) Saxagliptin and cardiovascular outcomes in patients with type\u00a02 diabetes mellitus. N\u00a0Engl J Med 369:1317\u20131326","DOI":"10.1056\/NEJMoa1307684"},{"key":"3628_CR24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","volume":"5","author":"Vora","year":"2014","unstructured":"Vora J, Christensen T, Rana A, Bain SC (2014) Insulin degludec versus insulin glargine in type\u00a01 and type\u00a02 diabetes mellitus: a metaanalysis of endpoints in phase\u00a03a trials. Diabetes Ther 5:435\u2013446","journal-title":"Diabetes Ther"},{"key":"3628_CR25","unstructured":"Home PD et\u00a0al (2014) Glycemic control and hypoglycemia with new insulin glargine 300\u00a0U\/ml in people with T1DM. Poster ADA 80-LB-2014"},{"key":"3628_CR26","unstructured":"Kopitar Z, Koss FW (1975) Pharmacokinetic behaviour of gliquidone (AR-DF\u00a026), a new sulfonyl urea. Summary of the studies so far (author\u2019s transl). [Pharmakokinetisches Verhalten von Gliquidone (AR-DF\u00a026), einem neuen Sulfonylharnstoff. (Zusammenfassung der bisherigen Untersuchungen)] Arzneimittel-Forschung. 25:1933\u20131938"},{"key":"3628_CR27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List\u00a0JF (2014) Long-term study of patients with type\u00a02 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962\u2013971","journal-title":"Kidney Int"},{"key":"3628_CR28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00304849","volume":"27","author":"Rabkin","year":"1984","unstructured":"Rabkin R, Ryan MP, Duckworth WC (1984) The renal metabolism of insulin. Diabetologia 27:351\u2013357","journal-title":"Diabetologia"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-014-3628-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-014-3628-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-014-3628-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:17:41Z","timestamp":1558570661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-014-3628-1"}},"subtitle":["Update"],"short-title":[],"issued":{"date-parts":[[2015,4,19]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["3628"],"URL":"https:\/\/doi.org\/10.1007\/s00108-014-3628-1","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,19]]}}}